Srdan Verstovsek
Medical Oncology · Houston, TXNPI 1598864100
Payments from drug & device makers
Across 671 payments — averaging $4310.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$2.4M
- Bristol Myers Squibb$167K
- AbbVie$58K
- Pharmaessentia USA Corporation$39K
- Novartis$32K
- GSK$31K
- plus $154K from 17 others
Across 9 payments — averaging $1563.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$8K
- Bristol Myers Squibb$6K
- Novartis$150
What the payments were for
- Consulting fees$297,14364%
- Speaking & faculty fees$150,40732%
- Travel & lodging$8,4042%
- Food & beverage$2,4631%
- Education$5,3431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 528 | $2,412,664 |
| Bristol Myers Squibb | 32 | $166,605 |
| AbbVie | 8 | $58,031 |
| Pharmaessentia USA Corporation | 12 | $38,526 |
| Novartis | 15 | $32,360 |
| GSK | 14 | $30,841 |
| Novartis Pharma AG | 11 | $27,709 |
| NS Pharma, Inc. | 6 | $22,400 |
| E.r. Squibb & Sons, L.L.C. | 8 | $20,413 |
| Karyopharm Therapeutics Inc. | 2 | $19,680 |
| CTI Biopharma Corp. | 6 | $18,429 |
| Ipsen Biopharmaceuticals, Inc | 11 | $16,400 |
| F. Hoffmann-la Roche AG | 3 | $5,940 |
| Blueprint Medicines Corporation | 3 | $5,688 |
| Amgen | 2 | $4,760 |
| Hikma Pharmaceuticals USA | 2 | $4,000 |
| Janssen Research & Development, LLC | 1 | $2,480 |
| Kyowa Kirin, Inc. | 1 | $1,875 |
| Jazz Pharmaceuticals Inc. | 2 | $1,650 |
| Alnylam Pharmaceuticals Inc. | 1 | $1,050 |
| Beigene USA, Inc. | 1 | $1,000 |
| Morphosys, US Inc. | 1 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAKAFI$50,629
- XPOVIO$19,680
- Vonjo$18,397
- BESREMI$14,165
- Inrebic$12,593
- TASIGNA$11,004
- RYDAPT$10,231
- JAKAVI_JAKAFI_ONCOLOGY$8,249
- PEMAZYRE$7,380
- Reblozyl$6,806
- RUXOLITINIB_JAKAFI_ONCOLOGY$5,502
- Non-Covered Product$5,280
- Kyprolis$4,760
- AYVAKIT$3,448
- NUCALA$3,250
- VILTEPSO$2,100
- Venclexta$1,837
- BRUKINSA$1,000
- Fedratinib$476
- AFINITOR$402
How this compares
$2,892,634 in reported general payments places this provider in the 80th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
- Sarina Piha PaulHouston$26M
- Jenny ChangHouston$17.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.